Xiaoran Han

机构：Shandong University, State Power Investment Corporation (China), Shandong Provincial Hospital, Pfizer (China) · ORCID：0000-0002-2435-4191

发表论文 26 篇 · 总被引 1762 次 · h-index 13

代表论文

• The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis (2016 · Oncotarget · 被引 803)
• Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK) (2018 · European Journal of Medicinal Chemistry · 被引 224)
• Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders (2020 · Journal of Medicinal Chemistry · 被引 189)
• Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets (2022 · Journal of the American Chemical Society · 被引 140)
• G-protein-coupled receptors regulate autophagy by ZBTB16-mediated ubiquitination and proteasomal degradation of Atg14L (2015 · eLife · 被引 98)
• Discovery of Selective Small Molecule Degraders of BRAF-V600E (2020 · Journal of Medicinal Chemistry · 被引 66)